FDA launches new priority review voucher program for select biopharmas

Sunosi (solriamfetol)

FDA conference hall
Biotech

Axsome moves 'closer to judgement day' for depression med

Axsome Therapeutics has agreed to a set of postmarketing conditions proposed by the FDA to get its depression drug back on track.
Annalee Armstrong Apr 19, 2022 10:00am